{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:01:10Z","timestamp":1785333670124,"version":"3.55.0"},"reference-count":124,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastrointest Pharmacol Ther"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), recognized as the most prevalent liver disease worldwide and a leading cause of liver transplantation, is closely associated with type 2 diabetes, cardiovascular disease, and metabolic dysfunction. Its multifactorial pathogenesis involves insulin resistance, lipotoxicity, gut dysbiosis, and dysregulated signaling involving multiple receptors and pathways, culminating in hepatic steatosis, inflammation, fibrosis, and, ultimately, cirrhosis. Emerging insights into bile acid metabolism, short-chain fatty acids, and fibrogenic mediators underscore the complexity of disease progression. Despite increasing global prevalence, effective pharmacological treatments remain limited. Resmetirom, a thyroid hormone receptor \u03b2 (THR-\u03b2) agonist, is currently the lone agent approved for treating metabolic dysfunction-associated steatohepatitis (MASH). Off-label use of vitamin E and obeticholic acid has met with some treatment success. Peroxisome proliferator-activated receptor (PPAR) agonists, novel antidiabetic agents, glucagon-like peptide 1 agonists, and sodium-glucose cotransporter 2 inhibitors have shown promising results in MASLD\/MASH; however, further data are needed to prove their efficacy and safety. While metformin has largely failed to demonstrate efficacy, hepatotoxicity remains an area of concern with statin therapy. Novel agents, such as fibroblast growth factor analogs, fatty acid synthase inhibitors, galectin-3 inhibitors, and stearoyl-CoA desaturase inhibitors, are in the early stages of development and trials, warranting further research in steatotic liver diseases. Despite encouraging advances, long-term safety, durability of response, and regulatory approvals remain key hurdles before these agents can be broadly implemented in clinical practice. This review summarizes current knowledge on the pathogenesis of MASLD\/MASH and the molecular pathways that may offer therapeutic potential in managing this widespread metabolic liver disease.<\/jats:p>","DOI":"10.4292\/wjgpt.v16.i4.110827","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:29:21Z","timestamp":1764905361000},"source":"Crossref","is-referenced-by-count":3,"title":["Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends"],"prefix":"10.4292","volume":"16","author":[{"given":"George S","family":"Zacharia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad H","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23052"},{"key":"B4","doi-asserted-by":"crossref","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 434-438","DOI":"10.1016\/S0025-6196(24)00530-5"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10667-5"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93465"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13956"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.011"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1042\/bst0311120"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23621"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904944106"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77812"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-199904000-00004"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2021.104441"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20283"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.193"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.149"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2226922"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031807"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2172671"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00880-z"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/nu15183970"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/nu15092211"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26991"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00025"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2018.05.002"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i37.13493"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9202-6"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0002"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.08.014"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0708"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.10"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/me.2008-0311"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22572"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702759104"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2019.06.004"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4103\/2231-4040.90879"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-13-17"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1476-5926-2-S1-S7"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23478"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp158"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-013-9468-6"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101231"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1991"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/00365520903114912"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4162\/nrp.2013.7.6.481"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113257"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2004.02.002"},{"key":"B50","unstructured":"Ers\u00f6z G, G\u00fcn\u015far F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005; 124-128"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12352"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2014.11.018"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001726"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.520"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1437"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"B59","unstructured":"Krupa KN, Nguyen H, Parmar M.   Obeticholic Acid. 2024 Jul 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.029"},{"key":"B62","unstructured":"Healio.   'Unfavorable benefit-risk': FDA panel votes against obeticholic acid approval for NASH [Internet]. Dec 26, 2024. [cited 27 December 2024]. Available from: www.healio.com"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.034"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.04.016"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70242-8"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.203"},{"key":"B68","unstructured":"Viking Therapeutics.   Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH) [Internet]. Jun 4, 2024. [cited 29, December 2024]. Available from: https:\/\/ir.vikingtherapeutics.com\/2024-06-04-Viking-Therapeutics-Announces-Positive-52-Week-Histologic-Data-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5805398"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61272-X"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.2017.38.4.192"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13057"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.832732"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1009894"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2021.03.012"},{"key":"B78","unstructured":"Zydus Lifesciences Ltd.   Zydus receives approval from DCGI for Saroglitazar Magnesium for treatment of Type II Diabetes [Internet]. Ahmedabad: Zydus Lifesciences Ltd. Feb 3, 2020. [cited May 5, 2025]. Available from: https:\/\/www.zyduslife.com\/public\/pdf\/pressrelease\/Zydus_SaroglitazarMg_Diabetes_approval.pdf"},{"key":"B79","unstructured":"Central Drugs Standard Control Organization.   Drugs [Internet]. New Delhi: Ministry of Health & Family Welfare, Government of India. [cited 5 May 2025]. Available from: https:\/\/cdscoonline.gov.in\/CDSCO\/Drugs"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102174"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205"},{"key":"B82","unstructured":"Inventiva.   Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH\/NASH and its financial position [Internet]. Daix (France): Inventiva. Jul 5, 2024. [cited 5 May 2025]. Available from: https:\/\/inventivapharma.com\/wp-content\/uploads\/2024\/07\/Inventiva-PR-NATiV3-and-fiancial-situation-updates-EN-07-05-2024.pdf"},{"key":"B83","unstructured":"Inventiva.   Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis [Internet]. Yahoo Finance. Apr 1, 2025. [cited 5 May 2025]. Available from: https:\/\/finance.yahoo.com\/news\/inventiva-announces-completion-enrollment-phase-210000499.html"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1185\/030079908x253870"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1892"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1438318"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.793203"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4675-2"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211000243"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4342-z"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12555"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8491742"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.015"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32832e2baf"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30320"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3892\/br.2012.18"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02729-1"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3292"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2548"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6156.1000410"},{"key":"B105","unstructured":"Kurniawan J, Teressa M. Insulin Use and The Risk of Hepatocellular Carcinoma: Insights and Implications. Acta Med Indones 2024; 107-113"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v7.i8.380"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-4-18"},{"key":"B108","unstructured":"Feingold KR.   Cholesterol Lowering Drugs. 2024 Feb 12. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01028-4"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0351"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014668"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.011"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.012"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000607"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00095"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00246-2"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2100"},{"key":"B119","unstructured":"Hepion Pharmaceuticals.   Hepion Pharmaceuticals initiates wind-down activities in Phase 2b \u2018ASCEND-NASH\u2019 trial [Internet]. Edison, NJ: Hepion Pharmaceuticals. Apr 19, 2024. [cited 1 January 2024]. Available from: https:\/\/hepionpharma.com\/news\/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial\/"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13816"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.296"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01495-3"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1668374"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100018"}],"container-title":["World Journal of Gastrointestinal Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2150-5349\/full\/v16\/i4\/110827.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2150-5349\/full\/v16\/i4\/110827.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:29:34Z","timestamp":1764905374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2150-5349\/full\/v16\/i4\/110827.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":124,"journal-issue":{"issue":"4"},"alternative-id":["110827"],"URL":"https:\/\/doi.org\/10.4292\/wjgpt.v16.i4.110827","relation":{},"ISSN":["2150-5349"],"issn-type":[{"value":"2150-5349","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}